Use of berberine in the preparation of medicines for the treatment and / or prevention of fatty liver disease
By using borynethol, the safety and efficacy issues of MASLD treatment have been resolved, achieving multi-faceted protection against metabolic-related fatty liver disease, including reducing hepatic lipid accumulation, improving serum lipoprotein metabolism, and inhibiting inflammatory responses.
Patent Information
- Application Number
- CN202511788233.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-01
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2045-12-01
AI Technical Summary
Currently, there are no safe and effective drugs for the treatment or prevention of metabolic-associated fatty liver disease (MASLD). Existing drug candidates have insufficient efficacy or significant side effects, and existing lifestyle interventions have limited effectiveness and poor adherence.
Using borynterol as the active ingredient, pharmaceutically acceptable injectable or oral formulations are prepared to reduce hepatic lipid accumulation, improve serum lipoprotein metabolism, alleviate pathological damage to liver tissue, and inhibit inflammatory cell infiltration.
Borencel exerts protective effects at multiple levels, effectively alleviating MASLD induced by a high-fat diet, reducing lipid accumulation in the liver, improving serum lipoprotein metabolism, alleviating pathological damage to liver tissue and inhibiting inflammatory cell infiltration, significantly reducing serum enzyme activity, and improving glucose metabolism disorders.
Smart Images

Figure CN121466067B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the use of borynethol in the preparation of medicaments for the treatment and / or prevention of fatty liver disease. Background Technology
[0002] Fatty liver disease, also known as fatty liver, is a condition characterized by fatty changes in hepatocytes, caused by various factors such as genetic predisposition, environmental factors, and metabolic stress. It can be classified into alcoholic fatty liver disease, metabolic dysfunction-associated fatty liver disease (MASLD), and other special types of fatty liver, with non-alcoholic fatty liver disease being the most common. The primary affected populations include obese individuals, those with metabolic syndrome, type 2 diabetes, and those who consume excessive amounts of alcohol over a long period.
[0003] MASLD, with a disease spectrum encompassing everything from simple hepatic steatosis to metabolic dysfunction-associated steatohepatitis (NASH), liver fibrosis, and even cirrhosis and hepatocellular carcinoma, has become the most common chronic liver disease worldwide, affecting more than a quarter of the adult population. The pathogenesis of MASLD is closely related to components of metabolic syndrome such as obesity, insulin resistance, and dyslipidemia. Its pathological mechanisms are complex, involving the interaction of multiple processes, including excessive lipid deposition in hepatocytes, insulin resistance, oxidative stress, inflammatory responses, and apoptosis.
[0004] Currently, lifestyle interventions (such as dietary control and increased exercise) remain the preferred clinical management approach for MASLD. However, due to poor patient adherence and limited long-term efficacy, the effectiveness of this strategy is often unsatisfactory. More importantly, there is a lack of specific drugs approved by regulatory agencies worldwide for the treatment of MASLD. Although several candidate drugs targeting different pathological stages (e.g., farnesoid X receptor agonists, acetyl-CoA carboxylase inhibitors) are in clinical development, they either demonstrate insufficient efficacy or are accompanied by significant side effects, highlighting the urgent clinical need in this field for drugs with novel mechanisms of action and high safety and efficacy.
[0005] Modern pharmacological studies have shown that the pharmacological activity of *Pleurotus ostreatus* seeds is mainly attributed to their abundant lignans, with pleurotetraol and pleurotetraol being particularly abundant. Previous experiments have indicated that aqueous extracts of *Pleurotus ostreatus* seeds can alleviate acetaminophen (APAP)-induced liver injury by inhibiting the NF-κB pathway. Furthermore, previously reported literature suggests that pleurotetraol can treat non-alcoholic steatohepatitis by targeting PPARα.
[0006] Liu Jiamin, Isolation and Identification of Benzofuran Lignans in Melon Seeds and Study on their Anti-Hepatic Fibrosis Mechanism, Chengdu University, May 2025, published the anti-hepatic fibrosis efficacy of berberine (HPT). To date, neither publicly published academic papers nor patent literature have disclosed or suggested the therapeutic potential of berberine (HPT) for MASLD, especially lacking any indication of its effectiveness in improving hepatic lipid metabolism, reducing hepatic inflammation, and alleviating ballooning degeneration, which are key pathological processes. Therefore, there is an urgent need in this field to develop a new, safe, and effective drug for the prevention and / or treatment of MASLD. Summary of the Invention
[0007] This invention provides new uses for borencetetrol.
[0008] This invention provides the use of borencetetrol in the preparation of medicaments for the treatment and / or prevention of fatty liver disease.
[0009] The fatty liver disease mentioned above includes metabolic fatty liver disease, alcoholic liver disease, secondary fatty liver disease, mixed fatty liver disease, and cryptogenic fatty liver disease.
[0010] Preferably, the fatty liver disease is metabolic-associated fatty liver disease.
[0011] The drug described is used to reduce lipid accumulation in the liver, improve serum lipoprotein metabolism, alleviate pathological damage to liver tissue, and inhibit inflammatory cell infiltration.
[0012] The drug is prepared into a commonly used pharmaceutical formulation by adding berberine as the active ingredient and pharmaceutically acceptable excipients or auxiliary ingredients.
[0013] The preparation is either an injectable or oral preparation.
[0014] The present invention provides boryntheticol, which exerts a protective effect against high-fat diet-induced MASLD by reducing liver lipid accumulation, improving serum lipoprotein metabolism, alleviating pathological damage to liver tissue, and inhibiting inflammatory cell infiltration. Attached Figure Description
[0015] Figure 1 HPT alleviates FFA-induced intracellular lipid accumulation (A. BODIPY staining of HepG2 with / without HPT under FFA-induced conditions; B. ORO staining of AML12 with / without HPT under FFA-induced conditions). Figure 2.HPT therapeutic administration alleviated liver lipid accumulation and inflammation in HFD-fed mice (A. Mouse appearance; B. Statistical analysis of mouse body weight and liver weight; C. Analysis of liver to body weight ratio; D. Statistical analysis of brown adipose tissue, epididymal white adipose tissue, and inguinal adipose tissue weight; E. Detection and analysis of liver TG and TC levels; F. Detection and analysis of serum HDL-C and LDL-C levels; G. OGTT measurement and area under the curve analysis, as well as fasting blood glucose content detection and analysis; H. Detection and analysis of serum ALT and AST levels; I. Liver appearance, liver sections, HE, ORO, and BODIPY staining; J. Liver sections, F4 / 80 and CD45 staining. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). Figure 3 HPT prophylactic administration alleviated lipid accumulation and inflammatory infiltration in the liver of HFD mice (A. Mouse appearance; B. Statistical analysis of mouse body weight and liver weight; C. Statistical analysis of the ratio of mouse body weight to liver weight; D. Fasting blood glucose level detection and analysis; E. Liver appearance and HE, ORO, and BODIPY staining of liver sections; F. F4 / 80 and CD45 staining of liver sections; G. Serum HDL-C and LDL-C level detection and analysis; H. Liver TG and TC level detection and analysis; I. Serum AST and ALT level detection and analysis. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). Detailed Implementation
[0016] Experimental Example 1: Efficacy test of borencetide in treating metabolic-related fatty liver disease according to the present invention. An in vivo MASLD model was established by feeding experimental animals a high-fat diet. Within this model, prophylactic and therapeutic drug administration models were established to simulate different clinical application scenarios of the drug. A fatty degeneration model was established by inducing HepG2 or AML12 cells with free fatty acids (FFA). The prophylactic or therapeutic effects of borencel were comprehensively evaluated by measuring triglyceride (TG) and total cholesterol (TC) levels and analyzing lipid accumulation using Oil Red O or BODIPY staining.
[0017] 1. Materials and Methods 1.1 Reagents and Antibodies Ethyl acetate, petroleum ether, ethanol, and xylene used for histological analysis were purchased from CHRON CHEMICALS (Sichuan, China); methanol and formic acid used for ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF / MS) were purchased from Supelco (Pennsylvania, USA); and the aspartate aminotransferase / alanine aminotransferase activity kit was purchased from Nanjing Jiancheng Biotechnology Institute.
[0018] 1.2 Animal Experiments Healthy male C57BL / 6J mice, approximately 6-7 weeks old, were selected and housed under standard conditions (ambient temperature 18-22℃, 12 / 12-hour light / dark cycle). All mice were fed standard rodent diet and had free access to purified water. A one-week environmental acclimatization period was conducted before the experiment. This experiment strictly followed EU Directive 2010 / 63 / EU on animal welfare and was approved by the Animal Ethics Committee of Chengdu University (Approval No.: C20220511). After the acclimatization period, the mice were randomly divided into the following four groups (n=6 per group): normal control group (fed control diet), model control group (fed high-fat diet), low-dose HPT treatment group (fed high-fat diet and administered 30 mg / kg HPT by gavage), and high-dose HPT treatment group (fed high-fat diet and administered 60 mg / kg HPT by gavage). The high-fat diet induction lasted for 8 weeks. From week 9 onwards, each treatment group was given the corresponding dose of HPT, while the normal control group and the model control group were administered an equal volume of 1% CMC-Na solution by gavage as a control. After the end of week 8 treatment, all mice were fasted for 12 hours. Subsequently, they were anesthetized by inhalation of isoflurane, and blood, liver tissue, inguinal white fat, epididymal white fat, and brown fat samples were systematically collected. Some liver tissue was immediately fixed in formalin solution for subsequent histopathological analysis. After sample collection, the mice were finally euthanized by cervical dislocation in accordance with animal ethics guidelines.
[0019] 2. Liver histopathological examination After the fixed liver tissue samples were gradually dehydrated, they were embedded in paraffin, cut into thin sections of about 4 μm, stained with hematoxylin and eosin (H&E), and frozen sections were used for Oil Red O staining.
[0020] 3. Immunohistochemistry After heat-fixing paraffin-embedded tissue sections in a 60°C oven for 2 hours, they were sequentially immersed in xylene I and II for 10 minutes each to completely dewax them. Next, they were hydrated using a gradient of ethanol (5 minutes each of anhydrous ethanol I and II → 5 minutes of 95% ethanol → 5 minutes of 70% ethanol → 5 minutes of 50% ethanol). Finally, they were rinsed three times with phosphate-buffered saline (PBS, pH 7.4), 5 minutes each time. The sections were then immersed in preheated sodium citrate retrieval solution (pH 6.0) and boiled in a microwave oven on high (800W), then reduced to medium (400W) and maintained at a gentle boil for 20 minutes. After naturally cooling to room temperature, they were rinsed three times with PBS. Subsequently, endogenous peroxidase inhibitor was added, and the sections were incubated at room temperature for 10 minutes to quench endogenous peroxidase activity, followed by rinsing three times with PBS. To reduce nonspecific binding, 5% bovine serum albumin (BSA) blocking solution was added, and the sections were blocked at room temperature for 30 minutes. Discard the blocking solution, add the diluted primary antibody working solution directly, and incubate overnight at 4°C in a humidified chamber. The next day, recover the primary antibody and wash thoroughly three times with PBS. Add the reaction enhancement solution, incubate at room temperature for 30 minutes, then add the corresponding HRP-labeled broad-spectrum secondary antibody, incubate at room temperature for 90 minutes, and wash again three times with PBS. For color development, add freshly prepared DAB chromogenic solution and monitor the color development process in real time under an optical microscope. When a brownish-yellow signal appears in the target area, immediately immerse the slide in water to terminate the reaction. Subsequently, counterstain the cell nuclei with hematoxylin staining solution for about 1 minute, and rinse with running water for 10 minutes to regain blue color. Rapidly dehydrate the slides sequentially with a gradient of ethanol (50% → 70% → 95% → anhydrous ethanol I, II), each step for about 1 minute, followed by clearing with xylene I and II for 5 minutes each. Finally, mount with neutral resin and cover with a coverslip. After mounting, dry the slides in the dark for 24 hours, then observe and acquire digital images under an upright optical microscope.
[0021] 4. Oral glucose tolerance test After the drug intervention period, mice underwent an oral glucose tolerance test to assess their glucose clearance capacity. Mice were fasted for 12 hours (with no restriction on water intake), and their fasting blood glucose (0 minutes) was measured as a baseline. Subsequently, mice were administered a 20% glucose solution via gavage at a dose of 2 g of glucose per gram of body weight. Blood samples were collected from the tail tip at 30, 60, and 120 minutes after glucose administration, and blood glucose concentrations were immediately measured using a glucometer. The glucose concentration-time curve was plotted, and the area under the curve was calculated to comprehensively evaluate the body's glucose tolerance.
[0022] 5. Cell experiments The HepG2 and AML12 cell lines used in the experiment were purchased from the Shanghai Cell Bank, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Duchenne Modified Iger's Medium (DEME) supplemented with 10% (v / v) fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. Cells were routinely cultured in a 37°C, 5% CO2 incubator. For experimental treatment, cells in the logarithmic growth phase were seeded at an appropriate density in cell culture plates. When cell confluence reached approximately 80%, subsequent model induction was performed. To simulate the lipotoxic environment of MASLD in vivo, an in vitro model was established. HepG2 and AML12 cells were exposed to a mixed free fatty acid stimulation solution containing 0.2 mM oleic acid and 0.1 mM palmitic acid for 24 hours. Control cells were treated with an equal volume of medium containing 0.5% fatty acid-free bovine serum albumin (BSA).
[0023] 6. Cell viability detection To assess the potential toxicity or protective effect of HPT on HepG2 and AML12 cells, the CCK-8 assay was used. HepG2 or AML12 cells in logarithmic growth phase were cultured at 5 × 10⁶ cells per well. 3 Cells were seeded at a density of [insert density here] in 96-well plates. After complete cell adhesion, the medium was replaced with different concentrations of HPT, and a blank control group (containing only culture medium and no cells) was set up. Each treatment was performed in 5 replicates, and cultured for another 24 hours. After culture, 10 μL of CCK-8 solution was added to each well, gently mixed, and incubated at 37°C in a 5% CO2 incubator for 2 hours in the dark. Subsequently, the absorbance of each well was measured at 450 nm using a multi-sensor microplate reader. Relative cell viability was calculated using the following formula: Cell viability (%) = [(Experimental group OD)] 450 - Blank group OD4 450 ) / (Control group OD 450 - Blank group OD 450 )]×100% 7. Statistical Analysis Experimental data are expressed as mean-standard deviation (SEM), and statistical analysis was performed using GraphPad Prism 10.0 software. Statistical comparisons between different groups were performed using one-way ANOVA and t-tests. P < 0.05 was considered statistically significant.
[0024] 8. Conclusion 8.1 Perentetol alleviates free fatty acid-induced lipid accumulation To investigate the effect of HPT on lipid accumulation in hepatocytes under metabolic stress, HepG2 and AML12 cell lines were used in the experiment. Cells were treated with different concentrations (10 μM, 5 μM, and 2.5 μM) of HPT for 24 hours, with or without palmitic acid (PA) / oleic acid (OA) mixed fatty acid stimulation. Oil Red O and BODIPY staining confirmed that PA / OA stimulation induced significant intracellular lipid accumulation, while treatment with all concentrations of HPT significantly reduced this lipid accumulation. Figure 1 (AB). The results showed that HPT has the effect of alleviating free fatty acid-induced hepatocellular lipid toxicity.
[0025] 8.2 Borencel alleviates HFD-induced hepatic steatosis and inflammation To verify the lipid-lowering effect of HPT in vivo, a high-fat diet-induced mouse model was established. Mice were randomly divided into four groups: a normal control group fed a control diet, and the model group and two treatment groups fed a high-fat diet. From week 9, the two treatment groups continued the high-fat diet while being administered 60 mg / kg and 30 mg / kg of boremteilol daily by gavage, respectively, for 8 weeks. Compared with the normal control group, the high-fat diet model group showed significantly increased body weight, liver weight, liver weight / body weight ratio, and the weights of inguinal white adipose tissue, epididymal white adipose tissue, and brown adipose tissue. Figure 2A -D). Conversely, compared to the model group, the HPT treatment group showed significant reductions in all of the above indicators. The results indicate that HPT can effectively alleviate systemic weight gain, liver lipid accumulation, and white adipose tissue buildup caused by a high-fat diet.
[0026] Key indicators such as liver lipid metabolism, histopathology, and inflammatory infiltration in mice were also analyzed. First, liver lipid content and serum lipoprotein levels were measured. Compared with the normal diet group, the high-fat diet model group showed significantly increased levels of TC and TG in the liver of mice. Figure 2E Meanwhile, serum lipid analysis showed that the low-density lipoprotein (LDL-C) level in the model group mice was significantly increased, while the high-density lipoprotein (HDL-C) level was significantly decreased. Figure 2F After HPT treatment, all of the above indicators were significantly reversed, indicating that HPT can effectively improve HFD-induced liver lipid accumulation and systemic lipid metabolism disorders.
[0027] Furthermore, by measuring fasting blood glucose and performing an oral glucose tolerance test (OGTT) on mice, it was found that compared with the normal diet group, the fasting blood glucose of mice in the high-fat diet-induced model group was significantly increased, and they showed sustained hyperglycemia and a larger area under the curve in the OGTT test. Conversely, the fasting blood glucose and OGTT area under the curve of mice in the HPT treatment group were significantly lower than those in the model group, indicating that HPT effectively improved the glucose metabolism disorder induced by a high-fat diet. Figure 2G Furthermore, serum biochemical markers revealed that after 16 weeks of high-fat diet feeding, the serum AST and ALT activities in the model group mice were significantly higher than those in the normal control group. HPT treatment significantly reversed this phenomenon, effectively reducing serum AST and ALT levels, demonstrating its clear protective effect against high-fat diet-induced liver damage in mice. Figure 2H ).
[0028] Furthermore, subsequent histopathological analysis further validated this conclusion. H&E staining results showed that HFD-fed mice exhibited severe steatosis and ballooning hepatocyte degeneration in their livers, while HPT treatment significantly alleviated these pathological damages. In addition, Oil Red O and BODIPY staining clearly demonstrated that HPT treatment effectively reduced lipid deposition in liver tissue, corroborating the aforementioned biochemical results. Figure 2I ).
[0029] Lipotoxicity-induced inflammatory response is another key feature of MASLD progression. Immunohistochemical staining to assess hepatic inflammatory cell infiltration revealed a significant increase in F4 / 80-positive macrophages and CD45-positive leukocytes in the liver of mice in the HFD model group. In contrast, the inflammatory cell infiltration in the liver of mice in the HPT treatment group was significantly improved. Figure 2J ).
[0030] To investigate the intervention effect of HPO on a high-fat diet-induced MASLD mouse model, we conducted an 8-week prophylactic drug administration experiment. Mice were randomly divided into two groups: a high-fat diet group and a high-dose HPO intervention group. The results are as follows: Compared with the HFD group, HPO intervention significantly inhibited the weight gain of mice. Simultaneously, the absolute liver weight, liver-to-body ratio, and inguinal and epididymal white adipose tissue weight were significantly reduced in the HPO group. Measurements of fasting blood glucose levels in mice showed that HPO intervention effectively reduced fasting blood glucose (…). Figure 3 AD).
[0031] Histopathological analysis of liver tissue revealed that hematoxylin-eosin, Oil Red O, and BODIPY staining all confirmed that HPO intervention significantly reduced lipid accumulation, steatosis, and hepatocyte ballooning degeneration in mouse livers induced by HFD. Figure 3 E). Immunohistochemical staining showed that HPO treatment significantly reduced the infiltration of F4 / 80 and CD45-positive inflammatory cells in the liver (E). Figure 3 F). Further biochemical tests showed that HPO significantly reduced liver triglyceride and serum low-density lipoprotein cholesterol levels (F). Figure 3 G), but had no significant effect on total cholesterol in the liver and serum high-density lipoprotein cholesterol levels (G). Figure 3 H). Furthermore, HPO intervention significantly reduced the activities of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), suggesting a protective effect against HFD-induced liver injury. Figure 3 I).
[0032] In the HFD-induced MASLD mouse model, compared with the control group, the HPT intervention group effectively downregulated mouse body weight, liver weight, and liver weight / body weight ratio. Histopathological analysis of liver tissue (HE, Oil Red O, BODIPY staining) showed that HPT significantly alleviated lipid accumulation and hepatocyte ballooning degeneration in the liver. Biochemical indicators showed that HPT treatment significantly reduced the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) in the liver and serum, indicating that it effectively improved HFD-induced liver function damage and lipid metabolism disorders. To evaluate the ameliorative effect of HPT on liver inflammation, immunohistochemical staining of liver tissue for F4 / 80 (macrophage marker) and CD45 (leukocyte marker) was performed. Histological analysis showed that compared with the HFD model group, the number of F4 / 80-positive cells and CD45-positive cells in the liver of mice in the HPT treatment group was significantly reduced, demonstrating that HPT can effectively alleviate HFD-induced hepatic inflammatory cell infiltration. In summary, HPT treatment can comprehensively alleviate fatty liver disease associated with metabolic dysfunction induced by HFD in mice, with beneficial effects specifically manifested in improving hepatic lipid dysfunction and inhibiting hepatic inflammatory response. In vitro experiments confirmed that in the FFA-induced hepatocyte MASLD model, Oil Red O and BODIPY staining, as well as the detection of intracellular TG and TC levels, showed that HPT can significantly reduce intracellular lipid accumulation in hepatocytes.
[0033] In summary, HPT treatment can exert a protective effect against high-fat diet-induced MASLD by reducing hepatic lipid accumulation, improving serum lipoprotein metabolism, alleviating pathological damage to liver tissue, and inhibiting inflammatory cell infiltration at multiple levels.
Claims
1. Use of borencetyl as the sole active ingredient in the preparation of medicines for the treatment and / or prevention of metabolic-related fatty liver disease.
2. The use according to claim 1, characterized in that: The drug described is used to reduce lipid accumulation in the liver, improve serum lipoprotein metabolism, alleviate pathological damage to liver tissue, and inhibit inflammatory cell infiltration.
3. The use according to claim 1, characterized in that: The drug is prepared into a commonly used pharmaceutical formulation with borencelene as the sole active ingredient and the addition of pharmaceutically acceptable excipients or auxiliary ingredients.
4. The use according to claim 3, characterized in that: The preparation is either an injectable or oral preparation.
